Danaher (DHR) PT Rises to $138 On GE Biopharma Acquisition - Needham
Tweet Send to a Friend
Needham & Company analyst, Stephen Unger, reiterated his Buy rating on shares of Danaher (NYSE: DHR) and raised his price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


